Inovio Pharmaceuticals, Inc.
INO· Nasdaq
INOInovio Pharmaceuticals, Inc.
Filed Aug 9, 2023 · 10-Q · 40 days after period end · 0001055726-23-000051
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $225.97K | $784.40K | $272.82K | $267.19K |
| Net Income | -$35.53M | -$108.50M | -$82.14M | -$128.70M |
| EPS Diluted | -$1.61 | -$0.46 | -$0.39 | -$0.83 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end
